SCHEMBL16070347

SCHEMBL16070347

C#Cc1cccc(Nc2ncc(OCc3cc(C(=O)NC)cc(OC)c3F)cn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.41
▸ FGFR4 P22455 4/20 0.41
▸ FGFR1 P11362 3/20 0.41
▸ PTK2 Q05397 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HPGDS O60760 1/20 0.40
▸ FGFR3 P22607 2/20 0.39
▸ CSNK2A1 P68400 2/20 0.39
▸ FGFR2 P21802 1/20 0.39
▸ NEK2 P51955 1/20 0.39
▸ ALKBH1 Q13686 1/20 0.39
▸ GAK O14976 3/20 0.38
▸ EGFR P00533 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ FBP1 P09467 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ SYK P43405 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16069790 0.91 PTK2 (0.42) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16070348 0.89 PTK2 (0.51) SCN9AFGFR4FGFR1PTK2CYP3A4
SCHEMBL16070363 0.86 POLB (0.44) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16070342 0.85 FGFR3 (0.41) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16070358 0.85 FGFR3 (0.47) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16070502 0.85 CDK9 (0.46) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16069792 0.84 PTK2 (0.44) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL17469985 0.82 PTK2 (0.45) SCN9AFGFR4FGFR1PTK2CYP3A4
SCHEMBL16070250 0.82 PTK2 (0.45) FGFR4FGFR1PTK2CYP3A4CYP2D6
SCHEMBL16070230 0.82 ULK1 (0.48) FGFR4FGFR1PTK2FGFR3FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701680-B2 Pyrimidine and pyridine compounds and their usage HUTCHISON MEDIPHARMA LIMITED (CN) 2017-07-11 — — US disclosed
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-01-28 — — US disclosed
WO-2014139465-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE FGFR3, FGFR1, FGFR4 SCN9A 3903/4885FGFR4 3/4885FGFR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback